Pharmacological Nrf2 activator is therefore expected to ameliorate insulin resistance by counteracting obesity-induced oxidative stress and inflammation and maintaining oxidant and antioxidant homeostasis. This evidence concerns the gene NFE2L2 and obesity disorder.